



## iTrack™ Canaloplasty to be Featured at the Congress of German Ophthalmic Surgery (DOC) 2023

California, USA, June 15, 2023 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that its proprietary iTrack™ technology portfolio for canaloplasty, a stent-free minimally invasive surgical procedure for glaucoma, will be featured during the official scientific program of the 35<sup>th</sup> International Congress of German Ophthalmic Surgery (DOC), which will be held from June 15-17, 2023.

Prof. Norbert Körber, MD, FEBO and Dr. Simon Ondrejka, MD, FEBO, glaucoma surgeons at the Augentrum Köln-Porz, Germany, will present the long-term results of their iTrack™ canaloplasty cohort via two presentations during the DOC scientific program:

Presentation 1:

**“5-year clinical effectiveness of ab-interno canaloplasty in controlled and uncontrolled glaucoma patients”**

Presentation 2:

**“5-year clinical effectiveness of ab-interno canaloplasty in reducing the medication burden in glaucoma patients”**

According to Prof. Koerber, canaloplasty via an ab-interno surgical technique offers utility in the earlier stages of the glaucoma disease process in reducing patient reliance on medications. “Glaucoma medications are associated with compliance issues. Canaloplasty is an ideal procedure as it mediates medication reduction with minimal risk and does not preclude future surgical approaches. It is a procedure that is safe and easily combined with other interventions, which is why there is growing interest in the procedure among cataract surgeons and other ophthalmologists, in addition to glaucoma surgeons,” commented Prof. Koerber.

“Not only is canaloplasty using the iTrack™ technology proven to reduce IOP up to 5 years postoperatively, as demonstrated by the wonderful work of doctors Koerber and Ondrejka, but it is also associated with a reduction in glaucoma medication burden. This is promising



news for glaucoma patients globally, for whom long-term medication use poses many lifestyle and financial challenges. We are very thankful to Prof. Koerber and Dr. Ondrejka for their pioneering work in support of canaloplasty,” said Tom Spurling, Nova Eye CEO.

Nova Eye Medical will present their leading *iTrack™ Advance* technology during the DOC at exhibit #U19.

---

## **ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the *iTrack™* portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

---

## **ABOUT CANALOPLASTY**

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm’s canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm’s canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm’s canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

*iTrack™ and iTrack™ Advance have a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.*



*The iTrack™ canaloplasty microcatheter has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The iTrack™ canaloplasty microcatheter is not cleared for the ab-interno surgical technique in the United States.*

*The iTrack™ Advance canaloplasty device has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.*

For additional information about the iTrack™ Advance, including safety information, please visit: <https://itrack-advance.com/us>

Images are available at this link: <https://bit.ly/3GANwyR>

For media enquiries, please contact:

Kate Hunt: Nova Eye Chief Commercial Officer - [khunt@nova-eye.com](mailto:khunt@nova-eye.com)

Giorgio Pirazzini: GP Communications – [giorgio@gpcommunications.eu](mailto:giorgio@gpcommunications.eu)